Allegion US, a provider of security solutions, technology and services, will be exhibiting and demonstrating interoperable ...
And divarasib reduced the risk for death by 44% during the trial, with a median overall survival (OS) of 17.7 versus 12 ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; ...
Long-Term OS Results With Lenvatinib Plus Pembrolizumab and TACE in HCC / cancer, cancer care, Cancer research, cancer ...
The Blue Yeti made it easy to get started with a USB microphone, but there's plenty of competition now for anyone who wants ...
A summary of four recent studies evaluating locoregional therapies for hepatocellular carcinoma and percutaneous ablation for ...
TMT, has shown a strong tumor progression benefit in first-line, PD-L1-negative non-small cell lung cancer in a China phase 3 ...
Key Insights From ESMO 2026 / A. Benmaziane, B. Chibaudel, B. Goldenberg, biopsy, Breast Cancer, C. Coutzac, C. Cremolini, C.
In Panku-Lung01, iza-bren, an EGFRxHER3 ADC, significantly reduced the risk of progression or death by 60% compared with ...
Palo Alto Networks has disclosed an actively exploited vulnerability in the PAN-OS management interface that lets ...
In patients with muscle-invasive bladder cancer (MIBC), treatment with neoadjuvant durvalumab and enfortumab vedotin, with or ...
It will take at least several years for the results of clinical trials to be published. However, we can see "what questions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results